Category: BioTech

BioTech

Biotech Gainers: Arrowhead Research (NASDAQ:ARWR), DARA Biosciences (NASDAQ:DARA), Synthetic Biologics (NYSEMKT:SYN), Oncothyreon (NASDAQ:ONTY)

Equities research analysts at Deutsche Bank assumed coverage on shares of Arrowhead Research Corp (NASDAQ:ARWR) in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $45.00 price target on the stock. Arrowhead Research Corp (NASDAQ:ARWR) stock performance was 24.46% in last session and finished the day at $26.31. Traded volume was 7,684,553 million shares in the … Continue reading Biotech Gainers: Arrowhead Research (NASDAQ:ARWR), DARA Biosciences (NASDAQ:DARA), Synthetic Biologics (NYSEMKT:SYN), Oncothyreon (NASDAQ:ONTY)

Mark DeFrance
BioTech

Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Peregrine Pharmaceuticals (NASDAQ:PPHM), MannKind Corporation (NASDAQ:MNKD), Synta Pharmaceuticals (NASDAQ:SNTA)

Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has been trading with ups and downs since the past few days, after the company announced better-than-expected results and its plans to partner for its flagship drug Iclusig. One of the major takeaway during the earnings call is Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s CEO Harvey Berger’s indication for potential partnership in Japan for Iclusig, as the formal announcement is expected to come … Continue reading Biotech Active Stocks: Ariad Pharmaceuticals (NASDAQ:ARIA), Peregrine Pharmaceuticals (NASDAQ:PPHM), MannKind Corporation (NASDAQ:MNKD), Synta Pharmaceuticals (NASDAQ:SNTA)

Kevin Long
BioTech

Stocks Making Noise After-Hours: Sanchez Energy (NYSE:SN), RigNet (NASDAQ:RNET), China New Borun Corp (NYSE:BORN)

Sanchez Energy (NYSE:SN) is higher in the after hours session after the company reported financial results for Q4 improved year-over-year, with record revenue growth, despite falling short of analysts’ expectations. Shares are up 1.22% at $29.90, with a 52-week range of $17.02 – $32.96. The independent oil and natural gas exploration and production company reported Q4 adjusted earnings of $0.27 per share, compared with the … Continue reading Stocks Making Noise After-Hours: Sanchez Energy (NYSE:SN), RigNet (NASDAQ:RNET), China New Borun Corp (NYSE:BORN)

Colin Pettis
BioTech

Peregrine Pharmaceuticals (NASDAQ:PPHM) Up 20% to 19-Month High; Agenus (NASDAQ:AGEN) Soars

Peregrine Pharmaceuticals (NASDAQ:PPHM) is up nearly 20% and reached a 19-month high after the biopharmaceutical company said Wednesday that it will present data from three preclinical studies highlighting the immuno-oncology and anti-viral potential of phosphatidylserine (PS)-targeting antibodies. Results will be presented at two upcoming Keystone Symposia to be held March 9-13. Shares of Peregrine (NASDAQ:PPHM) are at $2.29, and earlier touched $2.37 – its highest price … Continue reading Peregrine Pharmaceuticals (NASDAQ:PPHM) Up 20% to 19-Month High; Agenus (NASDAQ:AGEN) Soars

Ryan Holtz
BioTech

Biotech Gainers: Insys Therapeutics Inc (NASDAQ:INSY), Oxygen Biotherapeutics (NASDAQ:OXBT), Halozyme Therapeutics (NASDAQ:HALO), Cytori Therapeutics (NASDAQ:CYTX)

Insys Therapeutics (NASDAQ:INSY) hit a new 52-week high during trading on Tuesday following a better than expected earnings announcement, AnalystRatings.NET reports. Insys Therapeutics Inc (NASDAQ:INSY) stock performance was 21.73% in last session and finished the day at $83.37. Traded volume was 1,203,992 million shares in the last session and the average volume of the stock remained 263.48 million shares. The beta of the stock remained … Continue reading Biotech Gainers: Insys Therapeutics Inc (NASDAQ:INSY), Oxygen Biotherapeutics (NASDAQ:OXBT), Halozyme Therapeutics (NASDAQ:HALO), Cytori Therapeutics (NASDAQ:CYTX)

Mark DeFrance
FB Nasdaq FB Facebook
BioTech

Biotech Active Runners: Novavax (NASDAQ:NVAX), VIVUS (NASDAQ:VVUS), Rexahn Pharmaceuticals (NYSEMKT:RNN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Novavax, Inc. (NASDAQ:NVAX), announced on Thursday that the Biomedical Advanced Research and Development authority extended the base period of performance of a contract with the pharmaceutical company for its recombinant seasonal and pandemic influenza vaccines. Novavax, Inc. (NASDAQ:NVAX) stock performance was 1.27% in last session and finished the day at $6.38. Traded volume was 13,436,282 million shares in the last session and the average volume … Continue reading Biotech Active Runners: Novavax (NASDAQ:NVAX), VIVUS (NASDAQ:VVUS), Rexahn Pharmaceuticals (NYSEMKT:RNN), Ariad Pharmaceuticals (NASDAQ:ARIA)

Colin Pettis